# achondroplasia FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/achondroplasia

> 15 upcoming FDA catalysts in achondroplasia: VOXZOGO (vosoritide, BMRN) on February 28, 2027 (PDUFA date); YUVIWEL® (navepegritide, ASND) on September 2027 (primary completion); YUVIWEL® (navepegritide, ASND) on Sep to Dec 2027 (topline data readout); VOXZOGO (vosoritide, BMRN) on December 2027 (primary completion); and 11 more.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: quarter only, exact day, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA decisions for achondroplasia?

15 upcoming FDA catalysts in achondroplasia: VOXZOGO (vosoritide, BMRN) on February 28, 2027 (PDUFA date); YUVIWEL® (navepegritide, ASND) on September 2027 (primary completion); YUVIWEL® (navepegritide, ASND) on Sep to Dec 2027 (topline data readout); VOXZOGO (vosoritide, BMRN) on December 2027 (primary completion); and 11 more. SEC Form 10-Q: "•In July 2026, we announced that the FDA accepted our sNDA for full approval of VOXZOGO in children with achondroplasia, with a PDUFA target action date of February 28, 2027." [Calendar and source filings](https://sec-api.dev/indications/achondroplasia)

Source: SEC Form 10-Q, accession 0001048477-26-000023, https://www.sec.gov/Archives/edgar/data/1048477/000104847726000023/bmrn-20260930.htm (retrieved 2026-11-12). Last confirmed 2026-11-03. Cite: https://sec-api.dev/indications/achondroplasia#answer

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Q2 2025 | [TransCon (transcon) topline data readout](https://sec-api.dev/pdufa/transcon) | ASND | achondroplasia | scheduled | " Topline COACH combination trial (TransCon CNP + TransCon hGH) data expected in Q2 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1612042/000119312525110062/d795154dex991.htm)) |
| Q2 2025 | [Ascendis Pharma A/S topline data readout](https://sec-api.dev/companies/asnd/catalysts) | ASND | achondroplasia | scheduled | "Topline Week 26 results from our Phase 2 COACH Trial in children with achondroplasia are expected in the second quarter of 2025." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1612042/000095017025061850/asnd-20250331.htm)) |
| August 6, 2026 | [VOXZOGO (vosoritide) NDA/BLA acceptance](https://sec-api.dev/pdufa/vosoritide) | BMRN | achondroplasia | completed | "•In July, BioMarin announced that the FDA accepted its sNDA for full approval of VOXZOGO in children with achondroplasia, with a Prescription Drug User Fee Act (PDUFA) target action date of February 28, 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1048477/000104847726000015/earningsrelease-6aug26ex991.htm)) |
| February 28, 2027 | [VOXZOGO (vosoritide) PDUFA date](https://sec-api.dev/pdufa/vosoritide) | BMRN | achondroplasia | scheduled | "•In July 2026, we announced that the FDA accepted our sNDA for full approval of VOXZOGO in children with achondroplasia, with a PDUFA target action date of February 28, 2027." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1048477/000104847726000023/bmrn-20260930.htm)) |
| September 2027 | [YUVIWEL® (navepegritide) primary completion](https://sec-api.dev/pdufa/navepegritide) | ASND | Achondroplasia | scheduled | "NCT06732895 (A Clinical Trial to Evaluate Efficacy and Safety of Navepegritide in Adolescents (12 - 18 Years of Age) With Achondroplasia.): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-09 (ESTIMATED); Lead Sponsor Ascendis Pharma A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06732895)) |
| Sep to Dec 2027 | [YUVIWEL® (navepegritide) topline data readout](https://sec-api.dev/pdufa/navepegritide) | ASND | Achondroplasia | scheduled | "NCT06732895 (A Clinical Trial to Evaluate Efficacy and Safety of Navepegritide in Adolescents (12 - 18 Years of Age) With Achondroplasia.): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-09 (ESTIMATED); Lead Sponsor Ascendis Pharma A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06732895)) |
| December 2027 | [VOXZOGO (vosoritide) primary completion](https://sec-api.dev/pdufa/vosoritide) | BMRN | Achondroplasia | scheduled | "NCT02724228 (A Study to Evaluate Long-Term Safety, Tolerability, & Efficacy of BMN 111 in Children With Achondroplasia (ACH)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-12 (ESTIMATED); Lead Sponsor BioMarin Pharmaceutical." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT02724228)) |
| Dec 2027 to Mar 2028 | [VOXZOGO (vosoritide) topline data readout](https://sec-api.dev/pdufa/vosoritide) | BMRN | Achondroplasia | scheduled | "NCT02724228 (A Study to Evaluate Long-Term Safety, Tolerability, & Efficacy of BMN 111 in Children With Achondroplasia (ACH)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-12 (ESTIMATED); Lead Sponsor BioMarin Pharmaceutical." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT02724228)) |
| December 2027 | [VOXZOGO (vosoritide) primary completion](https://sec-api.dev/pdufa/vosoritide) | BMRN | Achondroplasia | scheduled | "NCT04554940 (A Clinical Trial to Evaluate Safety of Vosoritide in At-risk Infants With Achondroplasia): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-12 (ESTIMATED); Lead Sponsor BioMarin Pharmaceutical." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04554940)) |
| Dec 2027 to Mar 2028 | [VOXZOGO (vosoritide) topline data readout](https://sec-api.dev/pdufa/vosoritide) | BMRN | Achondroplasia | scheduled | "NCT04554940 (A Clinical Trial to Evaluate Safety of Vosoritide in At-risk Infants With Achondroplasia): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-12 (ESTIMATED); Lead Sponsor BioMarin Pharmaceutical." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04554940)) |
| December 2027 | [YUVIWEL® (navepegritide) primary completion](https://sec-api.dev/pdufa/navepegritide) | ASND | Achondroplasia | scheduled | "NCT06079398 (A Clinical Trial to Evaluate Efficacy and Safety of TransCon CNP Compared With Placebo in Infants (0 to <2 Years of Age) With Achondroplasia): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-12 (ESTIMATED); Lead Sponsor Ascendis Pharma A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06079398)) |
| Dec 2027 to Mar 2028 | [YUVIWEL® (navepegritide) topline data readout](https://sec-api.dev/pdufa/navepegritide) | ASND | Achondroplasia | scheduled | "NCT06079398 (A Clinical Trial to Evaluate Efficacy and Safety of TransCon CNP Compared With Placebo in Infants (0 to <2 Years of Age) With Achondroplasia): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-12 (ESTIMATED); Lead Sponsor Ascendis Pharma A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06079398)) |
| September 2028 | [Dual therapy with navepegritide and lonapegsomatropin primary completion](https://sec-api.dev/pdufa/dual-therapy-with-navepegritide-and-lonapegsomatropin) | ASND | Achondroplasia | scheduled | "NCT07924059 (Clinical Trial Evaluating the Efficacy and Safety of Navepegritide and Lonapegsomatropin in Achondroplasia): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2028-09 (ESTIMATED); Lead Sponsor Ascendis Pharma A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07924059)) |
| Sep to Dec 2028 | [Dual therapy with navepegritide and lonapegsomatropin topline data readout](https://sec-api.dev/pdufa/dual-therapy-with-navepegritide-and-lonapegsomatropin) | ASND | Achondroplasia | scheduled | "NCT07924059 (Clinical Trial Evaluating the Efficacy and Safety of Navepegritide and Lonapegsomatropin in Achondroplasia): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2028-09 (ESTIMATED); Lead Sponsor Ascendis Pharma A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07924059)) |
| June 2029 | [BMN-333 primary completion](https://sec-api.dev/pdufa/bmn-333) | BMRN | Achondroplasia | scheduled | "NCT07441876 (Study to Evaluate the Efficacy and Safety of BMN 333 Versus Vosoritide in Children With Achondroplasia): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2029-06 (ESTIMATED); Lead Sponsor BioMarin Pharmaceutical." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07441876)) |
| Jun to Sep 2029 | [BMN-333 topline data readout](https://sec-api.dev/pdufa/bmn-333) | BMRN | Achondroplasia | scheduled | "NCT07441876 (Study to Evaluate the Efficacy and Safety of BMN 333 Versus Vosoritide in Children With Achondroplasia): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2029-06 (ESTIMATED); Lead Sponsor BioMarin Pharmaceutical." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07441876)) |
| January 2030 | [Tyra-300 60mg primary completion](https://sec-api.dev/pdufa/tyra-300) | TYRA | Achondroplasia | scheduled | "NCT06842355 (A Study of TYRA-300 in Children With Achondroplasia: BEACH301): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2030-01 (ESTIMATED); Lead Sponsor Tyra Biosciences, Inc." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06842355)) |
| Jan to Apr 2030 | [Tyra-300 60mg topline data readout](https://sec-api.dev/pdufa/tyra-300) | TYRA | Achondroplasia | scheduled | "NCT06842355 (A Study of TYRA-300 in Children With Achondroplasia: BEACH301): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2030-01 (ESTIMATED); Lead Sponsor Tyra Biosciences, Inc." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06842355)) |

## Drugs

- [TransCon (transcon)](https://sec-api.dev/pdufa/transcon) (ASND)
- [VOXZOGO (vosoritide)](https://sec-api.dev/pdufa/vosoritide) (BMRN)
- [YUVIWEL® (navepegritide)](https://sec-api.dev/pdufa/navepegritide) (ASND)
- [Dual therapy with navepegritide and lonapegsomatropin](https://sec-api.dev/pdufa/dual-therapy-with-navepegritide-and-lonapegsomatropin) (ASND)
- [BMN-333](https://sec-api.dev/pdufa/bmn-333) (BMRN)
- [Tyra-300 60mg](https://sec-api.dev/pdufa/tyra-300) (TYRA)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/achondroplasia.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "achondroplasia FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/achondroplasia

```bibtex
@misc{secapidev_indications_achondroplasia_20261116,
  title        = {achondroplasia FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/achondroplasia}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_achondroplasia_20261116","title":"achondroplasia FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/achondroplasia","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
